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Integrins are transmembrane αβ glycoproteins that connect the extracellular matrix to the cytoskeleton. The 
laminin-binding integrin α3β1 is expressed at high levels in lung epithelium and in kidney podocytes. In podo-
cytes, α3β1 associates with the tetraspanin CD151 to maintain a functional filtration barrier. Here, we report 
on a patient homozygous for a novel missense mutation in the human ITGA3 gene, causing fatal interstitial 
lung disease and congenital nephrotic syndrome. The mutation caused an alanine-to-serine substitution in the 
integrin α3 subunit, thereby introducing an N-glycosylation motif at amino acid position 349. We expressed 
this mutant form of ITGA3 in murine podocytes and found that hyperglycosylation of the α3 precursor pre-
vented its heterodimerization with β1, whereas CD151 association with the α3 subunit occurred normally. 
Consequently, the β1 precursor accumulated in the ER, and the mutant α3 precursor was degraded by the 
ubiquitin-proteasome system. Thus, these findings uncover a gain-of-glycosylation mutation in ITGA3 that 
prevents the biosynthesis of functional α3β1, causing a fatal multiorgan disorder.
Introduction
The integrin family is comprised of 24 transmembrane heterod-
imeric αβ glycoproteins that link the extracellular matrix to the 
cytoskeleton (1). Most integrins connect to actin filaments and 
reside in cellular adhesion structures designated focal adhesions 
(FAs), which are highly enriched in tyrosine-phosphorylated 
proteins and serve as major hubs for signal transduction (2). 
Integrin-ligand binding can be controlled by conformational 
changes that tune integrin affinity (3). Furthermore, integrin 
function depends strongly on trafficking events, which include 
endocytosis, intracellular sorting and recycling, and delivery of 
de novo synthesized integrins to the plasma membrane by the 
biosynthetic route (4, 5). Both α and β subunits are synthesized 
as precursors. After N-linked glycosylation, folding, and associa-
tion of the α and β subunits in the ER, the heterodimer is trans-
ported to the Golgi network, in which the N-linked high-man-
nose oligosaccharides are further processed into complex 
oligosaccharides. Subsequently, several of the α subunit precur-
sors, including α3, are cleaved by proprotein convertases such as 
furin into a heavy and a light chain, which are held together by 
a disulphide bond to generate the mature form that is expressed 
at the plasma membrane (6, 7).
A number of human congenital disorders have been associ-
ated with defective integrin-mediated adhesion, including the 
blistering disorder epidermolysis bullosa (integrin α6β4 in 
epithelia), the bleeding disorder Glanzmann’s thrombasthenia 
(integrin αIIbβ3 on platelets), leukocyte adhesion deficiency-I 
(β2 integrins on leukocytes), and muscular dystrophy (integrin 
α7β1 in striated muscle) (8–11). Furthermore, the importance of 
integrins for cell adhesion in a variety of organ systems has been 
demonstrated by numerous mouse models targeting either inte-
grin subunits or integrin-associated proteins (12). For example, 
genetic deletion of the laminin-binding (LN-binding) epithelial 
integrin α3β1 in mice causes severe lung and kidney defects as 
well as abnormalities in the epidermis (13–17). In podocytes, 
which are the epithelial cells of the glomerulus of the kidney, 
α3β1 maintains cell adhesion under great dynamic stress by 
binding to LN-511/521 in the glomerular basement membrane 
(GBM). Integrin-LN binding is reinforced by intracellular con-
nection to the actin cytoskeleton via linker proteins, such as 
α-actinin or integrin-linked kinase, and by lateral association 
with the tetraspanin CD151 (18). The pivotal role of this mul-
ticomponent adhesion unit in regulating the barrier function 
of the kidney is illustrated by the severe glomerular defects 
observed in mice upon (podocyte-specific) deletion of α3, β1, 
integrin-linked kinase, CD151, or the α5 chain of LN-511/521 
(19–25). In addition, mutations in the genes encoding the β2 
chain of LN-521, α-actinin-4, and CD151 have been identified 
in patients suffering from renal disorders, including Pierson 
syndrome, focal segmental glomerulosclerosis, and hereditary 
nephritis (26–28).
Here, we report a mutation in the human ITGA3 gene in a 
patient with interstitial lung disease and congenital nephrotic 
syndrome. The mutation leads to a gain of glycosylation, which 
impedes heterodimerization of the α3 precursor with β1 but not 
its association with CD151. As a consequence, the β1 precursor 
accumulates in the ER, and the mutant α3 precursor is cleared 
by ubiquitination and degradation by the proteasome. Thus, we 
have identified a gain-of-glycosylation mutation in ITGA3 that 
prevents the biosynthesis of functional α3β1, leading to severe 
kidney and lung defects.
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Results
A point mutation in ITGA3 causes congenital nephrotic syndrome and 
interstitial lung disease. We identified a patient born prematurely, 
at a gestational age of 36 weeks, to unaffected nonconsanguin-
eous Dutch parents. She had one unaffected sibling (Figure 1A). 
At birth, the patient presented with respiratory distress. The 
electrocardiogram was normal, and no structural heart defects 
were observed by ultrasound. However, lung biopsies revealed 
interstitial lung disease. In addition, renal ultrasound revealed 
unilateral kidney hypoplasia with hydronephrosis on the left 
side, and the patient was diagnosed with congenital nephrotic 
syndrome. Growth retardation was prominent, which could in 
part be attributed to prolonged steroid treatment and intermit-
tent feeding difficulties. The patient died at the age of 7 months 
due to respiratory insufficiency. We first screened known genes 
implicated in nephrotic syndrome (NPHS1, NPHS2, PLCE1, WT1, 
LAMB2, TRPC6, ACTN4, and INF2) and surfactant metabolism 
dysfunction, which is implicated in perinatal respiratory dis-
tress (ABCA3, SFTPB, and SFTPC). No mutations were detected 
in these genes (K.Y. Renkema, unpublished observations). Sub-
sequently, we conducted genome-wide screening in the patient 
and both parents for copy number variations (CNVs), using Affy-
metrix 250K SNP array analysis. The data have been deposited 
in NCBI’s Gene Expression Omnibus and are accessible through 
GEO Series accession number GSE40405 (http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE40405). Whereas no clinically 
relevant CNVs were detected, a 19.2-Mb long continuous stretch 
of homozygosity (36.78–55.97 Mb) was identified on chromo-
some 17, encompassing 1,261 SNP probes, with SNP_A_2105989 
and SNP_A_4223473 as bordering SNPs (Figure 1, B and C). The 
Figure 1
Identification of homozygosity for an ITGA3 mutation in a patient with interstitial lung disease and nephrotic syndrome. (A) Pedigree of the 
patient’s family. I:1 and I:2, the patient’s parents; II:2, the patient; II:1, the patient’s sister. (B) Results from the 250k SNP array performed on the 
patient’s DNA. Log2 test-over-reference ratio values (y axis) for SNP loci plotted against the position on chromosome 17 (x axis). Red dots rep-
resent the log2 ratio for each SNP locus (top panel). The effective hidden Markov model outcome, with a normal test-over-reference ratio of 0. Blue 
dots represent the mean log2 ratio of neighboring SNPs on the array, indicating no significant copy number gains or losses (middle panel). Idio-
gram of chromosome 17. Green marks represent heterozygous SNP calls at particular DNA loci. The red box indicates the homozygous 19.2-Mb 
region, reflected by a loss of heterozygous loci. The thickness of the blue line represents the likelihood of LOH (bottom panel). (C) Idiogram of 
chromosome 17. The homozygous region from 17q12 to 17q23.2 is boxed. (D) Sequence analysis of ITGA3 in the patient’s parents, the patient, 
and the patient’s sister. The patient is homozygous for a missense mutation (c.1045G>T), resulting in the amino acid substitution p.A349S. Both 
the parents and the sister are heterozygous for the mutation. (E) Schematic overview of the 26 exons of the ITGA3 gene. The location of the 
c.1045G>T mutation in exon 7 is indicated by an asterisk. (F) Domain organization of the integrin α3 subunit. The A349S mutation is located 
between 2 FG-GAP repeats in the extracellular β-propeller domain.
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region contained 566 genes, among which was the ITGA3 gene, 
which encodes the integrin α3 subunit. The possibility of uni-
parental disomy of chromosome 17 was excluded by investigat-
ing the Mendelian inheritance pattern of 4,854 SNPs that are 
located on chromosome 17 and which are present on the array 
(K.Y. Renkema, unpublished observations). We then directly 
sequenced the ITGA3 coding sequence, which revealed homozy-
gosity for a missense variant c.1045G>T, for which both par-
ents and the healthy sibling were heterozygous (Figure 1D). In 
contrast, the variant was not observed in 384 chromosomes of 
ethnically matched (Dutch) individuals. In addition, it has not 
been annotated in dbSNP, the NHLBI Exome Sequencing Proj-
ect, or our in-house database of 100 exome-sequencing projects. 
The ITGA3 gene extends over 34.5 kb and contains 26 exons. The 
identified mutation is located in exon 7 (Figure 1E). At the pro-
tein level, the mutation causes the substitution of alanine 349 
for serine (A349S) in an extracellular domain of α3 designated 
the β-propeller (Figure 1F). In summary, we have identified a mis-
sense mutation in ITGA3 in a patient with interstitial lung disease 
and congenital nephrotic syndrome.
The A349S mutation prevents integrin α3β1 expression in vivo and 
causes severe kidney and lung abnormalities. Congenital nephrotic syn-
drome is characterized by proteinuria, resulting from defects in 
the filtration barrier of the glomerulus. To characterize the defects 
that caused the congenital nephrotic syndrome in our patient, we 
performed histological examination of kidney biopsies. Severe 
abnormalities were observed, including aberrant glomerular mor-
phology and cystic dilation of tubuli and local protein casts as well 
as interstitial fibrosis and some inflammatory infiltrate. The GBM 
was irregularly thickened, and the glomeruli consisted of fewer and 
wider capillary loops covered by highly variable numbers of podo-
cytes. In addition, mesangiolysis and mesangial hypercellularity, 
occasional extracapillary proliferation reflecting a loss of capillary 
integrity, and focal segmental glomerulosclerosis were observed 
Figure 2
Abnormalities in the kidneys of the patient. (A) 
Jones’ silver staining of a section of patient 
kidney, showing a highly irregular mesan-
gium and fewer and wider capillary loops, with 
highly variable numbers of podocytes. The 
inset shows a fibrocellular crescent in a glom-
erulus undergoing glomerulosclerosis. Scale 
bar: 100 μm; 50 μm (inset). (B) Ultrastructural 
analysis of the filtration barrier of the kidney 
of the patient, demonstrating abnormal foot 
processes and thickening of the GBM with 
local protrusions. Ec, endothelial cell; Fp, foot 
processes; Pdc, podocyte. Scale bar: 1 μm. 
(C) Kidney cryosections were subjected to 
indirect immunofluorescence analysis. The 
images show glomeruli stained with anti-
bodies against the extracellular domain of 
α3e (J143; green) and podocin (red), CD151 
(green) and nidogen (red), α6 (green) and the 
cytoplasmic domain of α3 (α3c) (homemade 
polyclonal antibody; red), β1 (green) and LN 
(red), and control IgG (green) and collagen IV 
(red). Nuclei were counterstained with DAPI 
(blue). Scale bar: 50 μm.
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(R. Goldschmeding, unpublished observations; Figure 2A; 
and Supplemental Figure 1; supplemental material available 
online with this article; doi:10.1172/JCI64100DS1). Ultrastruc-
tural analysis revealed partial effacement of foot processes and a 
disorganized and thickened GBM, displaying a multilayered and 
pseudo-reticular structure with loose fragments, suggestive of a 
disturbance of the fusion process (Figure 2B and R. Goldschmed-
ing, unpublished observations).
We then investigated the expression and distribution of individ-
ual glomerular components by immunofluorescence analysis of 
kidney cryosections. In the patient’s glomeruli, the integrin α3 sub-
unit could not be detected, neither with antibodies J143 or P1B5, 
which are directed against the extracellular domain of α3, nor with a 
homemade antibody that recognizes the cytoplasmic tail (Figure 2C 
and A. Sonnenberg and R. Goldschmeding, unpublished obser-
vations). Some aspecific immunoreactivity was observed in focal 
patches of cells. These also reacted with control IgG and most likely 
consist of activated mesangial cells, which are known to express Fc 
receptors. In addition to the lack of α3, a dramatic decrease in the 
levels of the β1 subunit was visible, confirming that α3β1 is the 
main β1 integrin in the glomerulus. Also, the expression of podocin 
and CD151 seemed reduced in the glomeruli of the patient, whereas 
expression of the integrin α6 subunit appeared to be slightly 
increased. Furthermore, there was an increase in the expression 
and deposition of the GBM proteins LN, nidogen, and collagen IV, 
confirming the thickening of the GBM observed by electron 
microscopy (Figure 2C).
Next, we analyzed lung biopsies from the patient. There were also 
multiple abnormalities in the lung, including widened alveolar 
septa lined with reactive type II pneumocytes and increased num-
bers of alveolar macrophages, whereas the alveolar walls in an age-
matched healthy individual were lined with flat type I pneumocytes 
and contained virtually no reactive type II pneumocytes and no alve-
olar macrophages (Figure 3, A–C). Pronounced pulmonary intersti-
tial glycogenesis was detected by PAS staining (Figure 3D). In addi-
tion, we observed an abnormal deposition of surfactant by electron 
microscopy (R. Goldschmeding, unpublished observations). As in 
the kidney, α3 could not be detected by immunofluorescence anal-
ysis of lung cryosections, whereas the expression of α6 seemed to 
be increased (Figure 3E). Together, these data show that the A349S 
mutation leads to the lack of integrin α3β1 expression, causing 
severe abnormalities in the kidneys and the lungs.
The A349S mutation impairs the expression of mature α3 at the cell 
surface. To investigate the effect of the A349S mutation in vitro, 
we isolated glomeruli from Itga3fl/flCd151fl/flTrp53+/– mice, accord-
ing to the Dynabead perfusion method, as described previously 
(29). Outgrowing epithelial cells were sorted for the expression of 
podocalyxin and the absence of the endothelial cell marker CD31. 
The floxed Itga3 and Cd151 genes were deleted by adenoviral deliv-
ery of Cre-recombinase, and the absence of both proteins was 
confirmed by flow cytometry (Supplemental Figure 2). We then 
generated the A349S mutation in cDNA encoding human α3 and 
stably expressed either wild-type human α3 (α3WT) or mutant 
human α3 (α3A349S) in the α3/CD151-deficient podocytes by ret-
roviral transduction, followed by selection with zeocin. The podo-
cytes were also reconstituted with FLAG-tagged human CD151 to 
avoid possible differences in binding efficiency of murine CD151 
to human α3, because of sequence variability in the α3-binding 
QRD motif, which is KRD in the mouse (30).
We first determined the cell surface expression of various integ-
rin subunits and CD151 by flow cytometry. In line with the results 
of immunofluorescence analysis of the patient tissue, α3 was 
completely absent from the cell surface of podocytes expressing 
α3A349S, and β1 levels were strongly reduced (Figure 4A). In con-
trast, the cell surface expression of CD151, as well as that of the 
integrin subunits α2, α5, and α6, was similar in podocytes express-
ing α3WT or α3A349S.
Next, we analyzed the expression of precursor and mature α3 
by Western blotting. The α3 subunit is synthesized as a precur-
sor of approximately 150 kDa. After N-linked glycosylation in the 
Figure 3
Abnormalities in lung tissue of the patient. (A) H&E staining of a lung section from a healthy individual. Scale bar: 100 μm. (B) H&E staining of a 
lung section from the patient. Scale bar: 100 μm. (C) Keratin staining showing lining of the thickened alveolar septa with reactive type II pneumo-
cytes in patient lungs. Scale bar: 100 μm. (D) PAS staining demonstrating glycogen deposits in interstitial cells in the lungs of the patient. Scale 
bar: 25 μm. (E) Lung cryosections of the patient and a control were subjected to indirect immunofluorescence analysis using our homemade 
antibodies against the cytoplasmic tail of α3 (green) and collagen IV (red) or α6 (green) and nidogen (red). IgG was included as a control for 
antibody specificity. Nuclei were counterstained with DAPI (blue). Scale bar: 50 μm.
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ER and association with β1, the α3β1 heterodimer is transported 
to the Golgi. Here, processing of the N-linked oligosaccharides 
occurs, and the α3 precursor is cleaved into a heavy (~115 kDa) 
and a light chain (~35 kDa) (6, 7). The β1 subunit is synthesized as 
a partially glycosylated precursor of approximately 105 kDa and a 
more heavily glycosylated mature form of approximately 125 kDa 
that is expressed at the cell surface. Intriguingly, we clearly detected 
precursor α3A349S, though to a lesser extent than α3WT, suggesting 
that the mutant is either less expressed or that some degradation 
occurs. The mature product was nevertheless completely absent, 
as evidenced by the lack of the α3 light chain (Figure 4B). Consis-
tently, there was a large pool of β1 precursor but a dramatic reduc-
tion of mature β1, as compared with the level in podocytes express-
ing wild-type α3. This observation supports the results obtained 
by flow cytometry and suggests that the mutant α3 precursor fails 
to heterodimerize, leading to accumulation of β1 precursor and a 
strong reduction of mature β1. These data indicate that, whereas 
the A349S mutation does not impair the expression of precursor 
α3, it leads to a lack of the mature α3 subunit at the cell surface, 
probably because heterodimerization with β1 is prevented.
The A349S mutation impairs α3β1 heterodimerization but not the asso-
ciation of precursor α3 with CD151. To determine whether the A349S 
mutation indeed prevents heterodimerization of the α3 and β1 
subunits, we immunoprecipitated α3 from lysates of podocytes 
expressing α3WT or α3A349S. The α3 subunit was precipitated with 
either antibodies against its cytoplasmic tail (29A3) or antibodies 
that recognize its extracellular domain (J143 and P1B5), whereas 
detection of α3 was performed using our homemade antibodies 
directed against its cytoplasmic tail. On reducing gels, this anti-
body recognizes the precursor of α3 as well as the 35-kDa light 
chain of the mature α3 subunit. In lysates from podocytes express-
ing α3WT, all antibodies precipitated both mature α3 and the pre-
cursor, although the latter was recognized to a lesser extent by 
J143 and P1B5 than by 29A3. Precursor α3WT appeared as 2 bands, 
which likely represent the high-mannose form in the ER and the 
complex form after modification of the N-linked oligosaccharides 
in the Golgi apparatus. As expected, the β1 subunit was coprecipi-
tated with α3WT. In contrast, neither J143 nor P1B5 precipitated the 
α3A349S precursor, whereas 29A3 did precipitate precursor α3A349S 
but not the mature α3 or β1 subunits (Figure 5A). These results 
suggest that the α3A349S precursor does not associate with β1 and 
that J143 and P1B5 recognize a complex-dependent epitope on the 
α3 subunit. We then precipitated the β1 subunit from podocyte 
lysates, using either the MB1.2 or the 9EG7 antibodies. Intrigu-
ingly, 9EG7 almost exclusively precipitated the β1 precursor but 
little or no mature β1, whereas MB1.2 precipitated both the pre-
cursor and mature β1, together with mature α3WT. In contrast, 
precursor β1, but hardly any mature β1, was precipitated from 
lysates of podocytes expressing the mutant α3 subunit (Figure 5B). 
Furthermore, neither of the 2 antibodies against β1 coprecipitated 
α3A349S. These results confirm that the A349S mutation prevents 
association of the α3 subunit with β1 in cultured podocytes. To 
analyze whether heterodimerization was also impaired in the 
patient, we precipitated α3 with 29A3 from a lysate of patient lung 
tissue. Consistent with the observations in podocytes, both precur-
sor and mature α3, as well as β1, were coprecipitated with 29A3 
from tissue of an unaffected individual, whereas no mature α3 or 
β1 and only a small amount of precursor α3 was precipitated from 
patient tissue (Figure 5C). We then investigated the association 
of α3WT and α3A349S with CD151 in podocytes. For this purpose, 
Figure 4
The α3A349S mutation prevents expression of mature but not precursor α3 in podocytes. (A) Murine α3/CD151-deficient podocytes were retro-
virally transduced with human CD151 as well as with either human wild-type α3 (blue) or human α3 carrying the patient mutation (red), and 
positive cells were selected with zeocin. Cell surface expression of integrin subunits α2, α3, α5, α6, and β1 as well as CD151 was determined 
by flow cytometry. Green indicates cells incubated only with secondary antibody. (B) Expression of the α3 subunit (precursor [~150 kDa] and 
mature light (L) chain [~35 kDa]) as well as that of the β1, α2, and α6 subunits was investigated by Western blotting in whole-cell lysates (WCLs) 
of podocytes. Arrows in the second column indicate the mature β1 (top arrow) and precursor β1 (bottom arrow); arrows in the third and fourth 
columns indicate α2 and α6, respectively. 
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we performed immunoprecipitation experiments using either the 
11G5 antibodies against CD151 or M2, which is directed against 
the FLAG-tag. As a negative control, we included the TS151R anti-
bodies that recognize the QRD sequence in CD151 that interacts 
with α3 and thus can only bind to CD151 when not in complex 
with α3β1 (31, 32). Both M2 and 11G5 coprecipitated CD151 with 
precursor and mature α3WT as well as with β1, suggesting that 
CD151 can associate both with the α3 precursor and mature α3. 
In addition, both antibodies clearly coprecipitated CD151 with 
α3A349S but not with β1, indicating that association of CD151 with 
the mutant precursor is not impaired and that CD151-α3 associa-
tion can occur prior to the association of α3 with β1 (Figure 5D). 
As expected, the TS151R antibodies only precipitated CD151 and 
no integrin subunits. These data suggest that CD151 can associate 
with precursor α3 prior to α/β heterodimerization and that the 
A349S mutation prevents α3 heterodimerization with β1 but not 
its association with CD151.
Gain of glycosylation disrupts heterodimerization and cell surface expression. 
To understand the mechanism by which the A349S mutation 
impairs α/β heterodimerization, we first determined the position 
of alanine 349 in the 3-dimensional structure of α3β1 by homol-
ogy modeling based on the recently resolved crystal structure of 
α5β1 (33). Alanine 349 is located on a loop opposite to the α/β 
interface, suggesting that a mutation at this site does not directly 
impair α3β1 heterodimerization by steric hindrance (Figure 6A). 
The A349S substitution introduces a novel N-glycosylation motif 
in α3 (N-x-A > N-x-S), indicating that it leads to a gain of glyco-
sylation. This was further suggested by the reduced mobility of 
the α3A349S precursor in gel electrophoresis on low-percentage gels, 
whereas both the α3WT and the α3A349S precursor migrated with 
similar mobility after incubation of the precipitated proteins with 
N-glycanase, an enzyme that cleaves all N-linked high-mannose 
oligosaccharides (Figure 6B). Alternatively, treatment of cells with 
tunicamycin, a pharmacological inhibitor of N-linked glycosyla-
tion, also abolished the difference in mobility between α3WT and 
α3A349S precursors, confirming that α3A349S was indeed hypergly-
cosylated (Figure 6C). However, the removal of all N-linked sug-
ars by tunicamycin did not rescue heterodimerization but instead 
induced degradation of both the α3 and β1 subunits, reflecting 
the essential role of N-glycosylation in protein stability. To demon-
strate that the addition of a sugar moiety prevents α/β heterodi-
merization, alanine 349 in α3 was substituted for glycine (α3A349G), 
which cannot be glycosylated, and the α3A349G mutant was intro-
duced in α3/CD151-deficient podocytes, as described above. 
Figure 5
The α3A349S mutation disrupts α3 het-
erodimerization with β1 but not CD151 
binding. (A) Podocytes expressing 
α3WT or α3A349S were lysed, and the α3 
subunit was precipitated using anti-
bodies against the cytoplasmic tail 
(29A3) or the extracellular domain 
(J143 and P1B5). Precipitated α3 and 
β1 were detected by Western blotting. 
(B) β1 was precipitated from podocyte 
lysates using 9EG7 or MB1.2, and α3 
and β1 were detected by Western blot-
ting. (C) The α3 subunit was precipi-
tated using 29A3 from tissue lysates 
of the patient and a healthy individual, 
and α3 and β1 were detected by West-
ern blotting. (D) FLAG-tagged CD151 
was precipitated from podocyte lysates 
using M2 against the FLAG-tag, 11G5 
against CD151, or TS151R that rec-
ognizes the QRD sequence in CD151 
when not in complex with α3. J143 
was included as a control. CD151, α3, 
and β1 were subsequently detected by 
Western blotting.
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Intriguingly, flow cytometry indicated that α3A349G was expressed 
at normal levels on the cell surface (Figure 6D). Consistent with 
this result, immunoprecipitation followed by Western blotting 
demonstrated that the α3A349G precursor is normally cleaved to 
generate the mature product and that α3A349G indeed associates 
with the β1 subunit (Figure 6E). Thus, whereas the A349S sub-
stitution has dramatic consequences, substitution of alanine 349 
with glycine has no effect. In line with this result, alignment of 
the amino acid sequence of α3 from different species revealed that 
a glycine, as well as an arginine or asparagine but not a serine or 
threonine, at this position occurs naturally in some organisms, 
further suggesting that sequence variation at this site is not detri-
mental per se, whereas the introduction of a novel oligosaccharide 
is (Supplemental Figure 3). Taken together, these data suggest that 
the A349S mutation leads to a gain of glycosylation, which pre-
vents α3β1 heterodimerization and cell surface expression.
Heterodimerization and cell surface expression of α3A349Sβ1 are not 
impaired by association with CD151. Complex formation with CD151 
requires an extracellular region in the α3 subunit comprising 
amino acids 570–705, adjacent to the loop containing alanine 349 
(32). Because binding of CD151 to the α3A349S precursor is not 
impaired, we hypothesized that the association of CD151 with 
α3A349S may affect the orientation of the oligosaccharide in such 
a way that it induces a conformational change, thereby prevent-
ing its heterodimerization with β1. To explore this possibility, 
we introduced either α3WT or α3A349S, but not CD151, in α3/
CD151-deficient podocytes and investigated their expression at 
the cell surface by flow cytometry. Similarly to that in podocytes 
that express CD151, α3WT but not α3A349S was expressed at the 
cell surface in CD151–/– cells (Figure 7A). Accordingly, in lysates 
of CD151–/– cells reconstituted with α3WT, both the precursor and 
mature α3 subunits were detected by Western blotting, while in 
lysates of CD151–/– cells expressing the mutant α3A349S, only the 
precursor α3 subunit was present (Figure 7B). These results were 
further confirmed by the lack of expression of mature α3A349S, 
but not of α3WT, in podocytes that contain CD151, in which the 
α3-binding glutamine-arginine-aspartic acid (QRD) at amino 
acid position 194–196 was mutated to isoleucine-asparagine-phe-
nylalanine (INF) (Figure 7B). This demonstrates that the associ-
ation of CD151 with α3A349S is not the cause of defective α3β1 
Figure 6
The α3A349S mutation introduces a glycosylation motif that impairs heterodimerization and cell surface expression. (A) Model of the ectodomain of 
α5β1 and α3β1. The N-x-A motif is indicated by an arrow. (B) The α3 subunit was precipitated with 29A3, the precipitates were treated with N-glyca-
nase, and α3 and β1 were detected by Western blotting. (C) Podocytes expressing either α3WT or α3A349S were cultured for 16 hours in the absence 
or the presence of tunicamycin (1 μg/ml), after which expression of the α3 subunit was analyzed by Western blotting. (D) Alanine 349 was mutated 
to glycine in human α3, and the α3A349G mutant was expressed in α3-deficient podocytes by retroviral transduction and selection with zeocin. Cell 
surface expression of α3 and β1 in α3WT-expressing (blue) or α3A349G-expressing (red) cells was then investigated by flow cytometry. Green indi-
cates cells incubated only with secondary antibody. (E) Expression of precursor and mature α3A349G as well as heterodimerization with β1 were 
investigated by precipitation of α3 with antibody 29A3 from lysates of podocytes expressing either α3WT or α3A349G, followed by Western blotting.
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heterodimerization, cleavage of precursor α3, and cell surface 
expression and suggests that the introduction of an additional 
oligosaccharide side chain is by itself sufficient to disturb proper 
folding of the α3 subunit.
The A349S mutation causes accumulation of the α3 and β1 precursors in 
the ER, α3 ubiquitination, and proteasomal degradation. We next inves-
tigated the subcellular distribution of α3WTβ1 and α3A349Sβ1 in 
podocytes by confocal microscopy. First, we used the J143 antibod-
ies against the extracellular domain of α3. As expected, α3WT was 
clearly distributed over the plasma membrane and was enriched 
laterally at cell-cell contact sites and basally in FAs, as indicated by 
colocalization with the FA marker phospho-paxillin. In contrast, 
no α3A349S was detected at the plasma membrane, consistent with 
the biochemical and flow cytometry data. Furthermore, J143 did 
not react with precursor α3A349S in intracellular compartments, 
supporting the idea that this antibody recognizes the α3 subunit 
only when it is associated with β1 (Figure 8A). In the presence of 
α3WT, β1 was distributed over the plasma membrane, laterally 
in cell-cell contacts and basally in FAs, as determined using an 
antibody directed against phosphorylated paxillin. However, in 
cells expressing α3A349S, there was hardly any β1 detectable at the 
plasma membrane, although the FA pool was retained. Instead, 
a dramatic accumulation was observed in a perinuclear compart-
ment, which was barely visible in cells expressing α3WT (Figure 8B). 
These observations are consistent with the dramatic reduction in 
β1 surface expression observed by flow cytometry and the large 
pool of β1 precursor found in lysates of α3A349S. The perinuclear 
distribution points, most likely, to the ER-localized excess of β1 
that cannot be heterodimerized with α3A349S. We then analyzed α3 
localization using our antibody directed against the cytoplasmic 
domain of α3. Much like the staining pattern obtained with J143, 
this antibody detected α3WT at the plasma membrane, in cell-cell 
contacts, and in cell-matrix adhesions. Intriguingly, it also revealed 
accumulation of α3A349S around the nucleus, where it is colocal-
ized with β1 (Figure 8, C and D). Finally, we examined the distribu-
tion of CD151. In cells expressing α3WT, CD151 is colocalized with 
α3 at the plasma membrane and in adhesions. In cells expressing 
α3A349S, CD151 was also localized at the plasma membrane, con-
sistent with observations that CD151 can traffic to the cell sur-
face independently of α3β1 (34). However, a small perinuclear 
pool colocalized with α3A349S, which probably represents CD151 
bound to precursor α3 in the ER (Figure 8E). Costaining of α3 or 
β1 with the ER markers protein disulphide isomerase or calnexin 
confirmed that the perinuclear compartment to which α3A349Sβ1 
is localized is indeed the ER (Figure 8F).
Calnexin is a chaperone protein that is involved in ER reten-
tion and folding of nascent glycoproteins (35). Both the integrin 
α and β subunit precursors undergo several cycles of folding and 
unfolding, during which calnexin associates with and dissociates 
from both to ensure that they reach their proper conformation 
before being transported to the Golgi (36). To investigate whether 
α3A349S could still associate with calnexin, we precipitated either 
β1 or α3 from podocytes expressing α3WT or α3A349S. Both wild-
type and mutant α3, as well as β1, coprecipitated from podocyte 
lysates with calnexin, indicating that the interaction of calnexin 
was not impaired with either subunit (Supplemental Figure 4). In 
an attempt to circumvent the quality control mechanism in the 
ER, we cultured podocytes at 30°C or incubated them with the 
pharmacological chaperones curcumin or 4-phenylbutyrate. Com-
pounds that can act as chaperones have been used to evade the ER 
response to misfolded G protein–coupled receptors, including the 
vasopressin receptor, gonadotropin-releasing hormone receptor, 
and cystic fibrosis transmembrane conductance regulator (37, 38). 
Therefore, pharmacological chaperones are suggested as treatment 
for a variety of diseases due to protein misfolding (39). However, 
neither strategy induced cell surface expression of α3A349S, whereas 
the cell surface expression of α3WT was increased (C. Margadant, 
unpublished observations).
Misfolded proteins are disposed of by the ER-associated degra-
dation pathway, which involves ubiquitination and transport from 
the ER to the cytosol for proteasomal degradation (40, 41). To 
inhibit the proteasome, podocytes were incubated for 6 hours with 
lactacystin (10 μM). Treatment with lactacystin induced a striking 
accumulation of polyubiquitinated α3A349S precursor, but much less 
Figure 7
CD151 binding does not impair α3β1 heterodimerization or transport 
of α3A349S to the plasma membrane. (A) α3/CD151-deficient podocytes 
were reconstituted with α3WT (blue) or α3A349S (red), and cell surface 
expression of α3 and β1 was analyzed by flow cytometry. Green indi-
cates α3WT incubated only with secondary antibody. (B) CD151-defi-
cient podocytes expressing either α3WT or α3A349S were lysed, and pre-
cursor and mature α3 were detected by Western blotting. Alternatively, 
α3/CD151-deficient podocytes were reconstituted with α3WT or α3A349S 
as well as with CD151, in which the QRD motif was mutated to INF. 
Podocytes were lysed, and precursor and mature α3 were detected by 
Western blotting.
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of α3WT, indicating that a large fraction of the mutant precursor is 
indeed ubiquitinated and proteasomally degraded (Figure 8G).
Together, these data demonstrate that the misfolded α3A349S pre-
cursor is cleared by ubiquitination and subsequent proteasomal 
degradation, whereas the excess of β1 that is unable to associate 
with α3A349S is mostly retained in the ER.
Discussion
Here, we report on a patient with a novel missense mutation in the 
ITGA3 gene, for which she is homozygous and which disturbs the 
biosynthesis of integrin α3β1, resulting in a multiorgan disorder, 
consisting of interstitial lung disease and congenital nephrotic 
syndrome. The mutation causes a gain of glycosylation in the α3 
Figure 8
The α3A349S mutation causes accumulation of β1 precursor in the ER and ubiquitination and proteasomal degradation of α3. (A) Subcellular 
localization of α3 was investigated in podocytes expressing either α3WT or α3A349S, using J143 against the extracellular domain of α3 (blue). Fil-
amentous actin (F-actin) was stained with phalloidin (red), and FAs were visualized using an antibody against phosphorylated paxillin [P(Y)pax; 
green]. (B) Localization of β1 (blue) in podocytes expressing either α3WT or α3A349S. Green indicates phosphorylated paxillin, and red indicates 
F-actin. (C) Distribution of α3 was investigated using an antibody directed against the cytoplasmic domain (blue), and FAs were detected with an 
antibody against phosphotyrosines [P(Y); green]. Red indicates F-actin. (D) Colocalization of β1 (green) and α3 (blue). Red indicates F-actin. (E) 
Distribution of CD151 (green) and α3 (blue). Red indicates F-actin. (A–E) Scale bar: 20 μm. Arrows indicate perinuclear localization of α3A349S 
and β1 in each panel. (F) Colocalization of α3A349S with protein disulphide isomerase (PDI; top) and β1 with calnexin (bottom). Nuclei were stained 
with DAPI. Scale bar: 20 μm. (G) Podocytes expressing either α3WT or α3A349S were treated for 6 hours with the proteasomal inhibitor lactacystin 
(10 μM) and lysed, and ubiquitinated α3β1 was detected by precipitation of the indicated subunits, followed by Western blotting.
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Our immunoprecipitation experiments yield some important 
conclusions. First, the mutant α3 subunit does not heterodimerize 
with β1, as shown by pull-down of either the α3 subunit with 29A3 
or the β1 subunit with MB1.2. Intriguingly, the 9EG7 antibody, 
which is widely used as a marker for β1 integrins in the active, 
high-affinity conformation (45), exclusively precipitated precur-
sor β1 but no mature β1. In addition, 9EG7 did not recognize β1 
on the cell surface by flow cytometry (C. Margadant, unpublished 
observations). These observations suggest that there is no β1 in 
its active conformation at the cell surface, questioning the use 
of 9EG7 as a bona fide marker for active β1 integrins in general. 
Second, the J143 and P1B5 antibodies, both directed against the 
extracellular domain of α3, apparently recognize a complex-depen-
dent epitope on the α3 subunit, because they do not precipitate 
precursor α3A349S, and precipitate much smaller amounts of the 
α3WT precursor than 29A3, but comparable amounts of mature α3 
or β1. The fraction of precursor α3 that is not recognized by these 
antibodies is presumably not associated with β1. Third, our data 
show that CD151 can associate with both the α3 precursor and 
mature α3, which is consistent with previous observations, indi-
cating that CD151-α3 association occurs early during biosynthesis 
of α3β1 (34). In addition, it has been shown that CD151 mutants 
that are not expressed at the cell surface can be coprecipitated with 
α3, suggesting that CD151 binds intracellular α3, of which at least 
a fraction consists of precursor (34). In fact, the observation that 
CD151 binds precursor α3A349S, even though the latter does not 
associate with β1, suggests that CD151-α3 association occurs 
prior to α/β heterodimerization.
The A349S mutation leads to hyperglycosylation of the α3 pre-
cursor, which is likely the cause of its disruptive effects, as (a) 
considerable sequence variability exists at this position among 
eukaryotes, but a serine or threonine is never encountered, and 
(b) a mutant carrying a glycine at this position, which cannot 
be glycosylated, associates normally with β1 and is expressed at 
the cell surface. As the novel sugar moiety is oriented away from 
the α/β interface, a direct effect on α/β subunit interaction by 
steric hindrance seems unlikely. However, it is located between 
subunit, which prevents heterodimerization with β1 but not the 
association with CD151. Although the mutant α3 subunit still 
interacts with calnexin, its misfolding is terminal, leading to rapid 
clearance by the ubiquitin/proteasome system while the noncom-
plexed β1 accumulates in the ER (Figure 9).
The kidney and lung abnormalities observed in the patient 
are consistent with the defects in kidney and lung morphogen-
esis observed in α3-deficient mice (13). In addition, we found 
extracapillary proliferation, focal segmental glomeruloscle-
rosis, and interstitial fibrosis in the glomeruli of the patient, 
which was not observed in α3-null mice. The latter observations 
likely reflect the progressive nature of the glomerular damage, 
as α3-deficient mice die much earlier after birth. In addition 
to the kidney and lung defects, absence of α3 in the epider-
mis causes skin abnormalities, including (micro-)blistering, 
basement membrane duplication, inflammation, and alopecia 
(13–17). Although obvious macroscopic skin abnormalities were 
not observed in the patient described here, we cannot exclude 
that microblistering or aberrant epidermal basement membrane 
organization occurred.
During the revision of this article, a report was published 
describing mutations in ITGA3. While the kidney and lung 
defects observed in the patients concerned are largely similar 
to those described here, an abnormal skin phenotype was also 
reported (42). It should be noted that the skin defects caused 
by α3 deficiency in mice are relatively minor, because adhesion 
of epidermal keratinocytes to LNs is rescued by other integrins, 
most notably the hemidesmosome-based integrin α6β4 (17, 43). 
Thus, redundant mechanisms exist in epidermal keratinocytes 
to ensure adhesion, which is probably why skin defects are not 
always detected in the absence of α3 (44). Similarly, a mutation 
in CD151 has been described to cause epidermolysis bullosa, 
whereas skin defects have not been observed in Cd151-deficient 
mice (19, 24, 25, 28). Nevertheless, α6 integrins cannot compen-
sate for the absence of α3β1 in the kidneys and the lungs, even 
though α6 expression seemed to be increased in these organs in 
the patient described here.
Figure 9
Model summarizing the biosynthetic route of 
CD151 and wild-type and mutant integrin α3β1. 
Newly synthesized α3 and β1 precursors, as well 
as CD151, undergo N-glycosylation and folding 
in the ER, facilitated by the chaperone calnexin. 
Thereafter, CD151 can associate with other 
tetraspanins or associate with the α3 subunit 
prior to α/β heterodimerization. Properly folded 
and assembled complexes then traffic to the 
Golgi apparatus as integrin α3β1 heterodimers, 
α3β1 heterodimers in association with CD151, 
or CD151 in complex with other tetraspanins. (A) 
In the Golgi, the high-mannose oligosaccharides 
are processed to complex type sugars, and the 
α3 subunit is cleaved into a heavy and a light 
chain to generate the mature α3β1 heterodi-
mer. (B) Gain-of-glycosylation mutations in an 
integrin subunit can cause a failure to reach the 
final conformation and thereby prevent α/β het-
erodimerization. The affected subunits are then 
cleared by the ubiquitin/proteasome system, 
whereas their partners accumulate in the ER.
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SNP array analysis. Genomic DNA was obtained from peripheral blood 
samples of the patient and her parents. CNV screening by means of 
microarray analyses was carried out on the Affymetrix GeneChip 250k 
(NspI) SNP array platform (Affymetrix Inc.), which contains 25-mer 
oligonucleotides representing a total of 262,264 SNPs. The average 
resolution of this array platform is 150–200 kb. Hybridizations were 
performed according to the manufacturer’s protocols. CNVs and long 
continuous stretch of homozygosity were determined using Copy Num-
ber Analyzer for Affymetrix GeneChip mapping software (CNAG ver-
sion 2.0). The average resolution of this array platform is 150–200 Kb. 
To investigate uniparental disomy, genotypes were called by Affymetrix 
Genotype Console Software v2.1.
Mutation analysis of ITGA3. To sequence the complete coding region of 
ITGA3 in genomic DNA, exon-flanking primers were designed with the 
Primer3 program (Supplemental Table 1), which is available online (http://
frodo.wi.mit.edu/). All coding exons of ITGA3 were amplified by PCR in 
a total reaction volume of 20 μl, which contained 50 ng DNA, 10 pmol 
of each primer, 50 nmol of MgCl2, 1x Taq buffer (Applied Biosystems 
Inc.), and 1 U Taq polymerase (Applied Biosystems Inc.). PCR products 
were sequenced in forward and reverse directions by Sanger sequencing 
on a 3730 DNA analyzer (Applied Biosystems Inc.) with dye-termination 
chemistry (Big Dye Terminator Cycle Sequencing Kit, version 1.1; Applied 
Biosystems Inc.). Sequence analysis was performed using Sequencher 
4.8 software. The identified gene variant was confirmed by bidirectional 
sequencing. Segregation analysis was performed by Sanger sequencing. 
Furthermore, we sequenced the ITGA3 gene in 192 healthy blood donors 
from The Netherlands. To determine whether the mutation was previ-
ously detected in reference populations, we used our in-house database of 
approximately 100 whole-exome sequencing experiments, dbSNP, and the 
Exome Variant Server of the NHLBI Exome Sequencing Project, which is 
available online (http://evs.gs.washington.edu/EVS/).
Generation of cell lines, cell culture, cloning, and retroviral transduction. Glo-
meruli were isolated from Itga3fl/flCd151fl/flTrp53+/– mice, according to the 
Dynabead perfusion method as described previously (29), and cultured on 
3 μg/ml collagen I at 37°C and 5% CO2 in keratinocyte serum-free medium 
(K-SFM; Gibco BRL) supplemented with 50 μg/ml bovine pituitary extract, 
5 ng/ml EGF, 100 U/ml penicillin, and 100 U/ml streptomycin. Outgrow-
ing epithelial cells were sorted for expression of podocalyxin and absence 
of CD31. The Itga3 and Cd151 genes were deleted by adenoviral delivery 
of Cre-recombinase. The A349S and A349G mutations were generated by 
PCR overlap extension method, using a cDNA encoding human full-length 
α3A as a template. Wild-type ITGA3 was isolated by digestion with SacI and 
ligated into pUC18-a3. After digestion with SphI, ITGA3 was ligated into 
LZRS-IRES-zeo, which was transfected into Phoenix packaging cells using 
the calcium phosphate method. Virus-containing supernatant was isolated 
after 48 hours, and stable expression in the α3/CD151-deficient podocytes 
was achieved by retroviral transduction, followed by selection with zeocin 
(200 μg/ml). The podocytes were also reconstituted with a cDNA encoding 
FLAG-tagged human CD151.
Immunoprecipitation and Western blotting. Cell lysis and immuno-
precipitation were performed essentially as described previously (17). 
Whole cell lysates and precipitates were resolved by SDS-PAGE, transferred 
to polyvinylidene difluoride membranes (Millipore), and analyzed by West-
ern blotting. Bound antibodies were detected using the ECL detection sys-
tem from GE Healthcare.
Immunohistochemistry, electron microscopy, confocal microscopy, and flow 
cytometry. Electron microscopy and immunohistochemistry were per-
formed using standard procedures. For indirect immunofluorescence, 
cryosections from patient biopsies or coverslips with cells were incubated 
with antibodies as previously described (17). Images were acquired at room 
2 FG-GAP repeats, which form β-strands in the β-propeller 
domain. This region is very important for the proper folding of 
integrin α subunits, and numerous mutations in the β-propeller 
of αIIb have been identified that disturb its folding and the het-
erodimerization with β3 (46). Similar to what we have observed, 
such mutations lead to proteasomal degradation of the mutant 
αIIb precursor, whereas the noncomplexed β3 precursor is 
retained in the ER (47).
The repertoire of gain-of-glycosylation disorders is ever-
expanding, and gain-of-glycosylation mutations that disrupt 
integrin biosynthesis as the cause for a human disorder have 
previously been identified in the genes encoding integrin sub-
units β2 (causing leukocyte adhesion deficiency) and β3 (caus-
ing Glanzmann’s thrombasthenia) (48–50). We now report a 
new gain-of-glycosylation mutation that prevents the biosyn-
thesis of integrin α3β1, causing interstitial lung disease and 
congenital nephrotic syndrome. It will be important to imple-
ment ITGA3 gene sequencing in DNA diagnostics for newborns 
presenting with severe respiratory distress and/or congenital 
nephrotic syndrome of unknown etiology to facilitate early 
diagnosis in patients and provide recurrence risk estimation 
for patients and their relatives.
Methods
Materials. The cDNA encoding CD151 was provided by M. Hemler 
(Dana-Farber Cancer Institute, Boston, Massachusetts, USA), and the 
cDNA encoding human α3 has been described previously (51). Mouse 
mAbs directed against human α3 were J143 (hybridoma from ATCC) 
and P1B5 (W. Carter, Fred Hutchinson Cancer Research Center, Seattle, 
Washington, USA). Mouse antibodies against human CD151 were 5C11 
(F. Berditchevski, University of Birmingham, Birmingham, United 
Kingdom), TS151R (E. Rubinstein, Hôpital Paul Brousse, Villejuif, 
France), and 8C3 (K. Sekiguchi, Osaka University, Osaka, Japan). The 
mouse mAb 29A3 against the cytoplasmic domain of α3A has been 
described previously (52). Rat mAbs were GoH3 against α6 and MB1.2 
against β1 (B. Chan, University of Ontario, Ontario, Canada). Rabbit 
polyclonal antibodies were directed against the cytoplasmic domain of 
α3A (19), the extracellular domain of α6 (AA6NT, ref. 53) (A. Cress, 
University of Arizona, Tucson, Arizona, USA), the cytoplasmic domains 
of β1A and α2 (G. Tarone, University of Turin, Turin, Italy), calnexin 
(I. Braakman, University of Utrecht, Utrecht, The Netherlands), col-
lagen IV (E. Engvall, The Burnham Institute, La Jolla, California, USA), 
LN and nidogen (T. Sasaki, Shriners Hospital for Children Research 
Center, Portland, Oregon, USA), and podocin (C. Antignac, Cochin 
Biomedical Research Institute, Paris, France). The goat antibody used 
against mouse α3 was AF2787 obtained from R&D Systems. TRITC- 
and FITC-conjugated secondary antibodies, phalloidin, and DAPI were 
obtained from Molecular Probes. HRP-conjugated secondary antibod-
ies were obtained from Amersham; curcumin, 4-phenylbutyrate, tuni-
camycin, and zeocin were obtained from Sigma-Aldrich; and collagen I 
was obtained from Vitrogen (Nutacon).
Patient material and DNA diagnostics. Peripheral blood samples were 
obtained from the patient and her parents and sibling after informed 
consent was given. Genomic DNA was extracted from these samples, and 
known genes implicated in nephrotic syndrome (NPHS1, WT1, PLCE1, 
LAMB2, NPHS2, TRPC6, ACTN4, INF2, ABCA3, TTF1, TTF2) and neona-
tal respiratory distress (ABCA3, SFTPB, and SFTPC) were screened for 
variants by Sanger sequencing. Tissue samples used in this study were 
derived from kidney and lung autopsy or biopsy specimens, obtained 
with informed parental consent.
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temperature with a confocal Leica TCS NT or AOBS microscope using 
×20 dry (numerical aperture 0.7), ×40 oil (numerical aperture 1.25), and 
×63 oil (numerical aperture 1.32) objectives (Leica) and AxioVision 4 soft-
ware (Carl Zeiss MicroImaging). Pictures were processed using Photoshop 
7.0 and ImageJ. Flow cytometry and cell sorting were performed as pre-
viously described (17).
Statistics. The 250k Affymetrix microarray data was analyzed using CNAG 
version 2.0 as previously described (54). CNVs were detected on the normal-
ized log2 ratios using a 5-state hidden Markov model with default settings 
(–1 μ, –0.3 μ, 0 μ, 0.38 μ, 0.55 μ). These settings were deemed appropriate 
as the autosomal standard deviation and the sex-mismatch mean ChrX 
were within the quality control ranges (less than 0.2 and greater than 0.3, 
respectively). Analysis for loss of heterozygosity (LOH) was also performed 
using CNAG version 2.0. This algorithm uses a maximum likelihood cal-
culation, with an inference based on the frequencies of heterozygous SNPs 
to determine significant stretches of LOH. A log-likelihood cut-off value 
of 15 was used to identify regions of LOH.
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